Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics

25-Jul-2008 - Roche and ARIUS Research Inc. announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million. ARIUS is the developer of a proprietary antibody platform called FunctionFIRST(TM), which rapidly ...

ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells

20-Feb-2008 - ARIUS Research Inc. announced that new information on the preclinical activity of its anti-CD9 cancer stem cell antibody will be presented at the AACR Special Conference on Cancer Stem Cells entitled "The Role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis," held on ...

ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody

07-Dec-2007 - ARIUS Research Inc. announced that it has entered into a manufacturing supply and technology transfer agreement for its CD44 Cancer Stem Cell antibody with Avid Bioservices, a company providing cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid has begun ...

Arius announces new findings in Trop-2 and CD59 CANCER antibody programs

CD59 antibody uses novel approach to "de-cloak" cancers

30-Oct-2007 - ARIUS Research Inc. announced that new findings have been presented from its Trop-2 and CD59 antibody programs. "Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in ...

ARIUS announces allowance of US patent for lead anti-cancer antibody

03-Aug-2007 - ARIUS Research Inc. announced that the Company has received notice from the United States Patent and Trademark Office that a key patent for its lead anti-CD44 drug candidate will issue on August 7th, 2007, as US Patent Number 7,252,821. This pivotal patent covers the ARH460-16-2 antibody itself, ...

US Patents Granted for ARIUS Antibodies

12-Mar-2007 - ARIUS Research Inc. announced that it has been granted two new United States patents for antibodies within their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS' partnered program for melanoma, breast and prostate cancers and protects the valuable site on the disease target ...

ARIUS Receives Six Key US Patents

Strengthens Intellectual Property Portfolio on Lead Programs and Antibody Assets

30-Nov-2006 - ARIUS Research Inc. announced that it has received Notices of Allowance from the United States Patent and Trademark Office for patents on their lead antibody, ARH460-16-2, targeting the CD44 antigen implicated as markers of cancer stem cells in breast and prostate cancer plus separate patents ...

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda

Three-Year Collaboration to look for Novel Cancer Treatments

06-Apr-2006 - ARIUS Research Inc. and Takeda Pharmaceutical Company Limited (Takeda) have entered into a three-year, multi-product collaboration using ARIUS' FunctionFIRST(TM) Platform to discover novel treatments for human disease. Under the terms of the agreement, ARIUS will receive an upfront technology ...

ARIUS Research Licenses Antibody to Genentech

24-Mar-2006 - ARIUS Research Inc. announced that it has licensed to Genentech, Inc. rights to one of ARIUS' novel anti-cancer antibodies and others in the same family for development in human disease. Under the terms of the agreement, ARIUS will receive an upfront licensing fee and may receive milestone ...